A comparison of the efficacy of Symbicort (R) [budesonide/formoterol] single inhaler therapy (Symbicort Turbuhaler (R) 160/4.5 Mg 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26 weeks, randomised, open-label, parallel-group multicentre study.

Trial Profile

A comparison of the efficacy of Symbicort (R) [budesonide/formoterol] single inhaler therapy (Symbicort Turbuhaler (R) 160/4.5 Mg 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26 weeks, randomised, open-label, parallel-group multicentre study.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2017

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms STYLE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Jul 2009 Additional locations identified as reported by ClinicalTrials.gov.
    • 11 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top